Genelux Corporation Common Stock Asset Resilience Ratio
Genelux Corporation Common Stock asset resilience ratio. Genelux Corporation Common Stock (GNLX) has an Asset Resilience Ratio of 52.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GNLX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genelux Corporation Common Stock (2022–2025)
Asset resilience ratio of Genelux Corporation Common Stock from 2022 to 2025. This chart shows how Genelux Corporation Common Stock's Asset Resilience Ratio has changed over time. Read debt load of Genelux Corporation Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genelux Corporation Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GNLX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.94 Million | 52.32% |
| Total Liquid Assets | $16.94 Million | 52.32% |
Asset Resilience Insights
- Very High Liquidity: Genelux Corporation Common Stock maintains exceptional liquid asset reserves at 52.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Genelux Corporation Common Stock Industry Peers by Asset Resilience Ratio
Compare Genelux Corporation Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Genelux Corporation Common Stock Asset Resilience Ratio by Year (2022–2025)
Genelux Corporation Common Stock asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Genelux Corporation Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.68% | $9.26 Million | $19.03 Million | -15.64pp |
| 2024-12-31 | 64.32% | $22.33 Million | $34.72 Million | +14.94pp |
| 2023-12-31 | 49.38% | $13.77 Million | $27.89 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $5.53 Million | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more